BRAIN Biotech Debt 2024

BRAIN Biotech Aktienanalyse

What does BRAIN Biotech do?

The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding BRAIN Biotech's Debt Structure

BRAIN Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BRAIN Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BRAIN Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BRAIN Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BRAIN Biotech Stock

What is the debt of BRAIN Biotech this year?

BRAIN Biotech has a debt level of 16.15 EUR this year.

What was the debt of BRAIN Biotech compared to the previous year?

The debt of BRAIN Biotech has increased by 603.22% compared to the previous year increased.

What are the consequences of high debt for investors in BRAIN Biotech?

High debt can pose a risk for investors of BRAIN Biotech, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of BRAIN Biotech?

Low debt means that BRAIN Biotech has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from BRAIN Biotech affect the company?

An increase in debt of BRAIN Biotech can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of BRAIN Biotech affect the company?

A reduction in debt of BRAIN Biotech can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of BRAIN Biotech?

Some factors that can influence the debt of BRAIN Biotech include investments, acquisitions, operating costs, and revenue development.

Why are the debts of BRAIN Biotech so important for investors?

The debts of BRAIN Biotech are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can BRAIN Biotech take to change the debt?

To change the debt, BRAIN Biotech can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does BRAIN Biotech pay?

Over the past 12 months, BRAIN Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BRAIN Biotech is expected to pay a dividend of 0 EUR.

What is the dividend yield of BRAIN Biotech?

The current dividend yield of BRAIN Biotech is .

When does BRAIN Biotech pay dividends?

BRAIN Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BRAIN Biotech?

BRAIN Biotech paid dividends every year for the past 0 years.

What is the dividend of BRAIN Biotech?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is BRAIN Biotech located?

BRAIN Biotech is assigned to the 'Commodities' sector.

Wann musste ich die Aktien von BRAIN Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BRAIN Biotech from 5/27/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.

When did BRAIN Biotech pay the last dividend?

The last dividend was paid out on 5/27/2024.

What was the dividend of BRAIN Biotech in the year 2023?

In the year 2023, BRAIN Biotech distributed 0 EUR as dividends.

In which currency does BRAIN Biotech pay out the dividend?

The dividends of BRAIN Biotech are distributed in EUR.